Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Overview
Nevro Corp (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California. The company is renowned for its innovative approach in the field of neuromodulation and chronic pain management, providing advanced spinal cord stimulation (SCS) systems designed to transform patient outcomes. Nevro specializes in the development and commercialization of its flagship Senza SCS system, which uniquely delivers its proprietary 10 kHz high-frequency therapy. This evidence-based treatment is implemented through a comprehensive, integrated platform aimed at alleviating chronic pain across multiple conditions.
Technology and Innovation
Nevro’s technology centers on generating electrical impulses that modulate pain signals. The Senza system, along with the broader HFX platform, is built on groundbreaking research and clinical evidence. Its design incorporates sophisticated programming and, more recently, artificial intelligence enhancements through HFX AdaptivAI. This AI-driven component harnesses big data, precise algorithms, and extensive clinical outcomes to offer personalized, real-time pain relief. As a result, patients are empowered to control their pain management in a manner that is tailored to their individual needs, reducing reliance on generalized treatments.
Product Portfolio and Market Position
The company has established a diversified portfolio that not only focuses on conventional SCS devices but also extends into minimally invasive treatments for sacroiliac (SI) joint pain and fusion procedures. By broadening its offerings, Nevro addresses various facets of chronic pain, including back pain, painful diabetic neuropathy, and SI joint dysfunction. This strategic diversification enables Nevro to maintain a unique competitive edge in a market characterized by substantial underpenetration and evolving treatment protocols.
Patient and Physician Support
An integral part of Nevro’s approach lies in its comprehensive support services. The company provides extensive educational resources and application support via programs like HFX Coach, designed to ensure that patients receive continuous guidance throughout their therapy journey. Alongside patient-centric initiatives, Nevro offers advanced, cloud-based insights for physicians, empowering them with real-time data to optimize treatment plans and enhance overall practice management.
Global Reach and Regulatory Milestones
Nevro’s neuromodulation solutions are commercially available in major markets such as the United States, Europe, and Australia. Over the years, the company has successfully achieved key regulatory approvals, including CE Mark and FDA clearance, which attest to the safety, efficacy, and scientific rigor underlying its products. These milestones have not only reinforced Nevro’s position in the global medical device arena but have also paved the way for further market penetration and adoption of its innovative therapies.
Competitive Landscape and Differentiators
Operating in a highly competitive healthcare sector, Nevro differentiates itself through an unwavering commitment to evidence-based medicine and technological innovation. Its products are developed with the dual aim of delivering consistent pain relief while also ensuring a high quality of life for patients. The use of advanced AI, coupled with extensive clinical validation, positions Nevro as an authoritative entity in chronic pain treatment options. This unique amalgamation of rigorous clinical research, technological sophistication, and robust support services sets Nevro apart from its peers in the neuromodulation industry.
Conclusion
Nevro Corp remains dedicated to advancing chronic pain management through its cutting-edge medical devices and holistic care solutions. With a focus on developing technologies that are not only innovative but also grounded in robust clinical evidence, Nevro continues to enhance patient outcomes and redefine approaches to pain management across global markets.
Nevro Corp. (NVRO), a medical device company, will report its fourth quarter and full-year financial results for 2020 on February 24, 2021, after market close. The conference call for discussing these results is scheduled for 1:30 PM PT/4:30 PM ET on the same day. Interested investors can join by dialing the provided numbers and using Conference ID 1353779. Nevro focuses on innovative chronic pain solutions, notably the Senza spinal cord stimulation system, which has shown efficacy in reducing opioid usage among patients.
Nevro Corp. (NYSE: NVRO) announced promising results from its HF10 therapy for chronic pain at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting, held January 14-16. The SENZA-PDN trial, with 216 randomized subjects, demonstrated significant pain relief in Diabetic Neuropathy patients over 6 months. The SENZA-NSRBP trial showed superior outcomes in Non-Surgical Refractory Back Pain patients after 3 months. The data supports a PMA supplement submission to the FDA for U.S. launch activities in the second half of 2021, marking a significant advancement in the treatment of chronic pain.
Nevro Corp. (NYSE: NVRO) announced significant data presentations for its HF10® therapy at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting.
The company will present 20 abstracts, including late-breaking results from the SENZA-PDN and SENZA-NSRBP trials. The SENZA-PDN trial is the largest of its kind, featuring 216 subjects. If approved, this could offer innovative treatment options for patients with chronic pain who have not found relief with traditional methods.
Nevro will also host an investor briefing on January 15, 2021, to discuss business updates.
Nevro Corp. (NYSE: NVRO) announced preliminary, unaudited revenue for Q4 and full-year 2020, revealing a decline in revenue amidst pandemic challenges. Q4 2020 revenue is projected at $109.7 million, a decrease from $114.4 million in Q4 2019. Full-year revenue is expected at $362.0 million, down from $390.3 million. U.S. trial procedures fell approximately 8%. Despite these declines, the company aims to capture market share in the chronic pain sector and anticipates growth as COVID impacts lessen.
Nevro Corp. (NYSE: NVRO) submitted a pre-market approval supplement to the FDA for its Senza® System, targeting Painful Diabetic Neuropathy (PDN). CEO D. Keith Grossman highlighted this milestone as critical for patients lacking relief from pharmacologic treatments. If approved, the Senza System could launch in late 2021, potentially addressing the needs of 4 million U.S. diabetic patients suffering from PDN. The SENZA-PDN study, the largest of its kind, aims to provide safety and efficacy data, with results to be presented at the NANS 2021 meeting on January 15, 2021.
Nevro Corp. (NYSE: NVRO) will host a virtual investor briefing on January 15, 2021, at 4:00 PM PST during the 2021 North American Neuromodulation Society (NANS) Virtual Conference. Chairman and CEO D. Keith Grossman will provide updates on the company's developments, alongside CFO Rod MacLeod and CMO Dr. David Caraway. Key presentations include findings from the SENZA-Painful Diabetic Neuropathy (PDN) trial, the largest RCT of spinal cord stimulation completed, and the Non-Surgical Refractory Back Pain (NSRBP) study. Webcast details can be found on Nevro's website.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain solutions, announced that D. Keith Grossman, Chairman and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 4:30 PM ET. This event can be accessed via a live webcast available in the Investors section of Nevro's website. Nevro specializes in innovative medical devices, including the Senza spinal cord stimulation system, known for its HF10 therapy that significantly reduces opioid dependency in over 65% of patients.
Nevro Corp. (NYSE: NVRO) announced the dismissal of its patent litigation against Boston Scientific regarding high frequency spinal cord stimulation therapy. This agreement follows Boston Scientific's assurances in July 2018 about not planning to launch a competing system. After a favorable ruling from the U.S. Court of Appeals in April 2020, both parties agreed to drop the remaining claims in California. Ongoing patent cases will continue in Delaware and at the Patent Office for different spinal cord stimulation technologies.
Nevro Corp. (NYSE: NVRO) announced the appointment of Susan E. Siegel to its Board of Directors, effective December 2, 2020, succeeding Wilfred Jaeger. Ms. Siegel brings over thirty years of experience in the life sciences and healthcare sectors, including leadership roles in innovative technology at General Electric and Mohr Davidow Ventures. CEO D. Keith Grossman expressed gratitude to Jaeger for his contributions and welcomed Siegel, highlighting her potential impact on Nevro's growth in chronic pain management products, notably the Senza spinal cord stimulation system.
Nevro Corp. (NYSE: NVRO) has appointed Julie Dewey as the new Vice President of Investor Relations and Corporate Communications, effective immediately. With over 25 years of experience in investor relations and corporate communications within the medical technology sector, Dewey will enhance Nevro's communication strategies with investors and analysts. CFO Rod MacLeod highlighted her extensive background as beneficial for sustainable growth and financial performance. Dewey previously held senior roles at Wright Medical Group and other healthcare technology firms.
FAQ
What is the current stock price of Nevro (NVRO)?
What is the market cap of Nevro (NVRO)?
What is Nevro Corp's primary business?
Which products form the core of Nevro's portfolio?
How does Nevro's spinal cord stimulation system work?
In which markets are Nevro's products available?
What role does technology play in Nevro's treatments?
How does Nevro support its patients and healthcare providers?
What differentiates Nevro from other pain management companies?
What conditions do Nevro's therapies target?
